Dorsey Wright & Associates’s Genmab GMAB Stock Holding History

Dorsey Wright & Associates’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.73M	Buy	64,388 +19,551	+44%	+$586K	0.21%	95
2025 Q4	$1.38M	Buy	+44,837	New	+$1.4M	0.3%	92
2023 Q1	–	Sell	-87,451	Closed	-$3.71M	–	324
2022 Q4	$3.71M	Buy	+87,451	New	+$3.6M	1.08%	21
2022 Q1	–	Sell	-106,239	Closed	-$4.2M	–	305
2021 Q4	$4.2M	Sell	106,239 -4,471	-4%	-$186K	0.87%	48
2021 Q3	$4.84M	Buy	+110,710	New	+$4.97M	1.06%	32
2021 Q1	–	Sell	-84,674	Closed	-$3.44M	–	308
2020 Q4	$3.44M	Sell	84,674 -1,828	-2%	-$68.3K	0.51%	61
2020 Q3	$3.17M	Buy	86,502 +1,167	+1%	+$42.2K	0.57%	53
2020 Q2	$2.85M	Buy	+85,335	New	+$2.33M	0.58%	51

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dorsey Wright & Associates's GMAB Position: Q1 2026 in Review

Dorsey Wright & Associates increased its Genmab (GMAB) stake by 44% in Q1 2026, buying an estimated $586K and bringing the position to 64,388 shares worth $1.73M. The position accounts for 0.21% of the portfolio, ranked #95.

Dorsey Wright & Associates first reported a position in GMAB in Q2 2020 and has held it in 8 quarters since. The position peaked at $4.84M in Q3 2021. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Dorsey Wright & Associates held 64,388 shares of Genmab worth $1.73M as of Q1 2026.
Dorsey Wright & Associates bought 19,551 Genmab shares in Q1 2026, an estimated $586K.
Genmab made up 0.21% of Dorsey Wright & Associates's portfolio in Q1 2026, its #95 holding.
Dorsey Wright & Associates first reported a position in Genmab in Q2 2020 and has held it in 8 quarters since.
Dorsey Wright & Associates's Genmab position peaked at $4.84M in Q3 2021.
272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Dorsey Wright & Associates's 13F filing for Q1 2026, filed 6 May 2026.